Lili Wang

Lili Wang currently serves as the Director of CMC Bioassay at enGene since June 2024. Prior experience includes roles such as Director of Analytical Development at Mustang Bio from February 2022 to March 2024 and Associate Director of Analytical Development at Rubius Therapeutics from April 2020 to February 2022. Lili's earlier positions include Principal Scientist and Potency Group Lead at Solid Biosciences, Process Development Scientist at Amgen, Scientist and Project Lead at Agenus, and Research Scientist II at the Broad Institute. Lili's expertise encompasses biochemical and cell-based assay development, high-throughput screening, and analytical development, supported by a Ph.D. in Molecular Cell Biology from Paris-Sud University and a diverse educational background in biology and administrative studies.